Results 171 to 180 of about 39,803 (247)

Semaglutide and tirzepatide: Oral cavity effects of weight-loss therapies. [PDF]

open access: yesEXCLI J
Bernardo ME   +4 more
europepmc   +1 more source

Editorial: The impact of GIP/GIPR on metabolic diseases: how the field is evolving. [PDF]

open access: yesFront Endocrinol (Lausanne)
Habegger K   +5 more
europepmc   +1 more source

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. [PDF]

open access: yesMol Metab
Roell W   +15 more
europepmc   +1 more source

Hormonal predictors of the lean phenotype in humans. [PDF]

open access: yesBiomol Biomed
Ahmed MB   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy